Latest news and press releases about Burning Rock Biotech Limited (BNR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Price
| Price | $13.52 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | CN |
Valuation Ratios
| Price / Book | 0.18 |
| EV / EBITDA | 13.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.96% |
| Return on Invested Capital | -10.10% |
| Return on Assets | -7.53% |
| Gross Margin | 74.55% |
| Operating Margin | -11.37% |
| Net Margin | -11.53% |
Related companies: ADVB · AEMD · ALUR · AMS · AYTU · CODX · EKSO
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BNR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks